Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience
Autor: | Wojciech Majewski, Tomasz Dworzecki, Leszek Miszczyk, Jaroslaw Nieckula |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Urology Disease-Free Survival Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Invasiveness Muscle Skeletal Aged Cisplatin Aged 80 and over Chemotherapy Bladder cancer Genitourinary system business.industry Incidence (epidemiology) General Medicine Chemoradiotherapy Middle Aged medicine.disease Combined Modality Therapy Neoadjuvant Therapy Radiation therapy Oncology Urinary Bladder Neoplasms Toxicity Female business medicine.drug |
Zdroj: | Anticancer research. 40(10) |
ISSN: | 1791-7530 |
Popis: | Aim To evaluate our experience with radical radiotherapy and chemotherapy in patients with muscle-invasive bladder cancer. Patients and methods The study consisted of 27 patients treated with cisplatin-based chemoradiation (CCRT), 48 treated with radiation alone (RT), and 42 with locally advanced disease treated with neoadjuvant chemotherapy and radiation (neoCRT). Results The incidence of acute grade 3 or more genitourinary (GU) toxicity in the RT, CCRT and neoCRT groups was: 25%, 11% and 19%, respectively (p=0.029). The 3-year freedom from grade 2 or more GU toxicity was: 81%, 89%, 54%, respectively (p=0.36). The long-term outcomes of 3-year local control, overall survival, and disease-free survival were as follows: RT group: 74%, 61% and 55%; CCRT group: 76%, 76% and 56%; neoCRT group: 31%, 43% and 18%, respectively. Conclusion The preferable bladder-conserving approach is CRT, however RT alone might also be an option for appropriately selected patients. NeoCRT for those with locally advanced tumors remain unsatisfactory; adequate selection of patients for radical treatment is of importance. |
Databáze: | OpenAIRE |
Externí odkaz: |